ACURA PHARMACEUTICALS, INC
Acura Pharmaceuticals filed an 8-K disclosing two additional $100,000 loans from Abuse Deterrent Pharma, LLC, bringing the total secured promissory note principal to $11,294,279 with approximately $1,365,000 in accrued interest at 5.25%. The company used the funds for day-to-day operations and warns that without additional financing by mid-October 2026, it will be forced to furlough or lay off employees, terminate operations, or seek bankruptcy protection — which could result in a complete loss of shareholder value.
- Total principal balance on the secured promissory note to Abuse Deterrent Pharma, LLC reached $11,294,279 as of September 30, 2026.
- Accrued interest on the note totals approximately $1,365,000, with a base rate of 5.25% and a default rate of 7.5%.
- Two additional $100,000 loans were received on September 18, 2026 and October 2, 2026 from AD Pharma for day-to-day operations.
- The company states it will need to furlough/lay off employees or seek bankruptcy protection if financing is not secured by mid-October 2026.
- The note's maturity date and the FDA NDA acceptance deadline for LTX-03 both fall on December 31, 2026, per forward-looking statement risk.
Price data unavailable.
A publicly traded pharma company explicitly stating it may imminently seek bankruptcy protection and warning of a "complete loss of shareholder value" is a rare, maximum-severity red flag.
Acura is a micro-cap opioid abuse-deterrent technology developer trading on OTC Expert Market, reliant on a single lender (Abuse Deterrent Pharma, LLC) for survival financing while awaiting FDA action on LTX-03.
The company explicitly warns that failure to obtain additional financing by mid-October 2026 will force scaling back operations, furloughs, layoffs, or bankruptcy — potentially resulting in a complete loss of shareholder value. The note's default triggers include failure to pay within 5 days of due,
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.